EU Court Advances Understanding Of SPC Patent Puzzle
Executive Summary
Pharmaceutical companies will have a better idea of the conditions under which a supplementary protection certificate can be granted after an advocate general of the European court explained how a new legal test established last year should be used. However, lawyers caution that the opinion still leaves some aspects to be clarified.
You may also be interested in...
CJEU Ruling Could Prove Problematic For Gilead’s Truvada SPC
A ruling by the Court of Justice of the EU has attempted to clarify the situation regarding the conditions for a supplementary protection certificate, but while it may help to settle the UK case regarding Gilead’s combination HIV drug Truvada, one practitioner says the case raises more questions than it answers.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.